NIH grants accreditation to ImmunoSEB and ProbioSEB CSC3
image for illustrative purpose
Mumbai, Oct 22 In a major step forward towards innovation in preventive therapy, the National Institutes of Health (NIH)—the medical research arm of the US Department of Health and Human Services has granted an in-principle accreditation to systemic enzyme and probiotic supplements—ImmunoSEB and ProbioSEB CSC3 for its proven clinical efficacy to resolve 'Long-COVID' fatigue symptoms.
Advanced Enzyme Technologies Limited is one of the global innovators of the ImmunoSEB and ProbioSEB CSC3 molecules.
A panel of experts set up by the NIH recently published a fact sheet, which endorsed the fact that there is satisfactory clinical trial data to substantiate that ImmunoSEB and ProbioSEB CSC3 supplements are effective to moderate and resolve post-COVID fatigue and muscle weakness.
According to NIH, ImmunoSEB and ProbioSEB CSC3 supplements administered during clinical trials conducted on 200 adults with post-COVID fatigue and muscle weakness were proven to be effective after 14-days of treatment. It was also found that fatigue resolved among 91 percent individuals who consumed the enzyme and probiotic supplements for 14 days.
"The recently published NIH fact sheet vindicates our clinical innovation ability to resolve 'Long-COVID' induced fatigue symptoms. We are one of the global innovators to develop systemic enzyme and probiotic supplements, averred Abhijit K Rathi, Principal Scientist, AETL.
According to NIH fact sheet, several additional clinical trials are underway in Canada to investigate whether probiotic administration for up to 25 days reduces the duration and severity of symptoms of COVID-19 in about 84 adults aged 18 years and older with moderate forms of the disease who are not hospitalized.
